The share of corresponding/leading authors in scientific publications in drug discovery in Japan is expected to slightly decline from 95.59% in 2024 to 95.23% in 2028, indicating a stable but gradual downward trend. In comparison, the level stood at 95.65% in 2023. The year-on-year decrease suggests a negligible decline of approximately 0.09% annually over the forecast period. Over five years, the compound annual growth rate (CAGR) reflects a consistent but minor reduction in the dominance of corresponding or leading authorship.
Future trends to watch for include the potential increase in collaborative and cross-disciplinary research, which may further distribute author shares. Monitoring global shifts in research funding and publication practices could also inform future changes in authorship dynamics.
